FDA OKs New Hepatitis B Drug
Drug Called Tyzeka Suppresses Hepatitis B Virus
WebMD News Archive
Oct. 26, 2006 -- The FDA yesterday approved a new drug, called Tyzeka, to
treat chronic hepatitis B in adults.
In a large clinical trial, Tyzeka was shown to be an effective antiviral
agent, capable of suppressing the hepatitis B virus and improving liver
inflammation comparably to Epivir-HBV, one of five medications already approved
to treat chronic hepatitis B. Tyzeka is not a cure, however.
Hepatitis B is a serious viral infection that attacks the liver and can
cause lifelong infection, liver scarring (cirrhosis),
liver cancer, liver failure, and death.
The hepatitis B virus is spread when body fluid from an infected person
enters the body of an uninfected person, sometimes by sexual contact or blood
"In a typical year, an estimated 70,000 Americans become infected with
chronic HBV [hepatitis B], and some 5,000 of them will die of the complications
caused by the disease," says Stephen Galson, MD, MPH, and director of the
FDA's Center for Drug Evaluation and Research.
"Tyzeka offers prescribers another option for treating these
patients," Galson continues in an FDA news release.
Tyzeka is a new molecular entity, which is an FDA term for medication
containing an active substance that has never before been approved for
marketing in any form in the U.S.
Long-term benefits of Tyzeka are unknown.
Use of the drug has not been shown to reduce the risk of transmission of the
hepatitis B virus to others.
Tyzeka was studied in a yearlong international clinical trial that included
1,367 patients with chronic hepatitis B. The patients were at least 16 years
old; three-fourths were men.
The trial produced evidence of Tyzeka's antiviral effectiveness, including
the suppression of hepatitis B virus and improvement in liver inflammation.
In clinical studies, Tyzeka was generally well tolerated. The most common
side effects were elevated CPK (creatinine phosphokinase, an enzyme that marks
the breakdown of muscle tissue), upper respiratory tract infection, fatigue, headache,
abdominal pain, and cough.
Also, after several weeks to months of Tyzeka use, some patients developed
symptoms ranging from transient muscle pain to muscle weakness.
Those who developed muscle weakness experienced significant improvement in
their symptoms when Tyzeka was discontinued.